Emergency Preparedness and Response

About MCMi

MCMi logo – four diamond shapes with radiological and biohazard symbols, globe and test tubeThe Medical Countermeasures Initiative (MCMi) is an FDA-wide initiative to coordinate medical countermeasure development, preparedness and response, led by the Office of Counterterrorism and Emerging Threats in the Office of the Chief Scientist.

FDA plays a critical role in protecting the United States from chemical, biological, radiological, nuclear, and emerging infectious disease threats. FDA ensures that medical countermeasures (MCMs)—including drugs, vaccines and diagnostic tests—to counter these threats are safe, effective, and secure.

Together with U.S. government partners through the Department of Health and Human Services Public Health Emergency Medical Countermeasures Enterprise (PHEMCE), FDA helps define and prioritize requirements for MCMs in public health emergencies. This includes coordinating research, setting deployment and use strategies, and facilitating access to MCMs.

MCMi History

FDA launched disclaimer icon MCMi in August 2010 in response to a comprehensive, year‐long review of the PHEMCE. The review was ordered by the Department of Health and Human Services (HHS) Secretary  to assess our nation’s readiness for future public health emergencies, and improve our nation’s capacity to respond faster and more effectively to chemical, biological, radiological, nuclear (CBRN), and emerging infectious disease threats, such as pandemic influenza.

MCMi builds on programs already under way at FDA medical product centers, and devotes additional resources to foster the development and availability of medical products that will be needed to counter public health emergencies.


Sign up to receive email alerts on emergency preparedness and response topics from FDA, including medical countermeasures and emerging infectious diseases.

Information in this Section

FDA Strategic Priorities

FDA's strategic priorities include vital work to better prepare our nation to respond to and protect the American people in the event of a public health emergency, whether naturally occurring or man-made

Contact FDA

FDA's Office of Counterterrorism and Emerging Threats

Michael Mair, MPH

Acting Assistant Commissioner for Counterterrorism Policy, and Acting Director, Office of Counterterrorism and Emerging Threats

Page Last Updated: 10/23/2018
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English